This is the authors' abstract. We don't add key points for this paper.
A dose-response relationship was observed for upadacitinib efficacy; the 30-mg once-daily dose showed the greatest clinical benefit. Dose-limiting toxicity was not observed.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Guttman‐Yassky et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: